Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

(University of Colorado Anschutz Medical Campus) Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months.

Comments
%d bloggers like this: